- Trials with a EudraCT protocol (396)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
396 result(s) found for: High risk population.
Displaying page 1 of 20.
| EudraCT Number: 2021-004135-89 | Sponsor Protocol Number: D516FC00001 | Start Date*: 2022-04-07 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Sta... | |||||||||||||
| Medical condition: Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) DE (Ongoing) IT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-001585-15 | Sponsor Protocol Number: 2018-01671 | Start Date*: 2020-01-30 |
| Sponsor Name:Centre Hospitalier Universitaire Vaudois | ||
| Full Title: PTX3 genetically stratified randomized double-blinded allocation eventdriven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia | ||
| Medical condition: Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome in transformation (MDSit) who receive antifungal profylaxis during their treatment with an intensive chemotherapy regimen, inc... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-004026-17 | Sponsor Protocol Number: MK-3475-057 | Start Date*: 2016-01-13 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
| Full Title: A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High Risk Non-muscle Invasi... | |||||||||||||
| Medical condition: Non-Muscle Invasive Bladder Cancer (NMIBC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Trial now transitioned) FI (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) GR (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-001495-18 | Sponsor Protocol Number: 2010-04-23 | Start Date*: 2011-08-23 |
| Sponsor Name:Population health Research Institute | ||
| Full Title: Steroids in Cardiac Surgery (SIRS) trial | ||
| Medical condition: cardiac surgery | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-000799-92 | Sponsor Protocol Number: LPS14355 | Start Date*: 2015-12-31 | |||||||||||
| Sponsor Name:sanofi-aventis Groupe | |||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Alirocumab in insulin treated patients with type 1 or type 2 diabetes and with hyperchole... | |||||||||||||
| Medical condition: Hypercholesterolemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) ES (Completed) DE (Completed) NL (Completed) AT (Completed) FR (Completed) BE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-001099-21 | Sponsor Protocol Number: 2010-04-23 | Start Date*: 2011-05-19 |
| Sponsor Name:Population Health Research Institute | ||
| Full Title: SIRS Steroids In caRdiac Surgery Trial | ||
| Medical condition: From available evidence, corticosteroids attenuate the inflammatory response to CPB which is felt to contribute to morbidity and mortality in cardiac surgery patients. The meta-analysis of the lite... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-001974-33 | Sponsor Protocol Number: 08/014 | Start Date*: 2009-04-14 |
| Sponsor Name:Radboud University Nijmegen Medical Centre [...] | ||
| Full Title: mRNA-transfected dendritic cell vaccination in high risk uveal melanoma patients | ||
| Medical condition: Our study population consists of HLA-A2.1 positive patients with a high risk uveal melanoma (stage II) with proven expression of melanoma associated antigens tyrosinase and/or gp100. Patients are i... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-004192-12 | Sponsor Protocol Number: NL66079.029.18 | Start Date*: 2019-08-05 |
| Sponsor Name:Amsterdam UMC, location VU medical Center | ||
| Full Title: Oil- based versus water-based contrast media for hysterosalpingography (HSG) in infertile women with unevaluated indications: a randomized controlled trial | ||
| Medical condition: The research population consists of infertile couples who have tried to conceive for at least 12 months, or have oligo- or anovulation. We will focus on women with ovulation disorders, or at high r... | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: NL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-001818-16 | Sponsor Protocol Number: LT-CLL-001 | Start Date*: 2007-07-05 | ||||||||||||||||
| Sponsor Name:Vilnius University Hospital Santariskiu Clinics | ||||||||||||||||||
| Full Title: Phase II Study of High-dose Methylprednisolone and Rituximab in Previously Treated Patients with High Risk Chronic B Lymphocytic Leukemia | ||||||||||||||||||
| Medical condition: Treated high-risk chronic B lymphocytic leukemia. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: LT (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2022-001067-27 | Sponsor Protocol Number: 20604 | Start Date*: 2022-11-10 | |||||||||||||||||||||
| Sponsor Name:Bayer AG | |||||||||||||||||||||||
| Full Title: A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of i... | |||||||||||||||||||||||
| Medical condition: Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DK (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) NO (Trial now transitioned) LT (Trial now transitioned) HU (Trial now transitioned) ES (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) LV (Trial now transitioned) PT (Trial now transitioned) BG (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2007-007943-29 | Sponsor Protocol Number: EFC6521 | Start Date*: 2008-07-29 |
| Sponsor Name:sanofi-aventis recherche & développement | ||
| Full Title: A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk ... | ||
| Medical condition: The subjects who will participate to this clinical trial are cancer patients (i.e. patients with metastatic or locally advanced tumor of the lung, pancreas, stomach, colon/ rectum, bladder or ovary... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) HU (Completed) FR (Completed) AT (Completed) LV (Completed) EE (Completed) SE (Completed) SK (Completed) NL (Completed) PT (Completed) LT (Completed) BE (Completed) DK (Completed) CZ (Completed) FI (Completed) SI (Completed) IT (Completed) BG (Completed) ES (Completed) GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2016-002077-35 | Sponsor Protocol Number: EC-HEM-HGUGM-2016-01 | Start Date*: 2017-05-05 |
| Sponsor Name:José Luís Díez Martín | ||
| Full Title: CLINICAL TRIAL PHASE I / II, SINGLE-CENTER, HISTORICAL CONTROL, TO EVALUATE THE EFFECTIVENESS OF DONOR IL-15-STIMULATED NK CELLS POST TRANSPLANT INFUSION, IN ACUTE LEUKEMIA PATIENTS WITH POOR PROGN... | ||
| Medical condition: High risk acute myeloid leukemia | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-003595-11 | Sponsor Protocol Number: 2004-06-DP-119-RKF-25 | Start Date*: 2005-03-18 |
| Sponsor Name:Canadian Cardiovascular Collaboration, Population Health Research Institute, McMaster University | ||
| Full Title: PeriOperative ISchemic Evaluation study | ||
| Medical condition: Perioperative cardiac events frequently complicate non-cardiac surgery resulting in significant morbidity, mortality and cost. There is no clear evidence from RCTs on how to lower perioperative ca... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DK (Completed) ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-003268-25 | Sponsor Protocol Number: AT-03A-017 | Start Date*: 2023-05-12 | |||||||||||
| Sponsor Name:Atea Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 | |||||||||||||
| Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Trial now transitioned) ES (Ongoing) LV (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-003190-99 | Sponsor Protocol Number: 38RC13.410 | Start Date*: 2015-12-09 |
| Sponsor Name:CHU de Grenoble | ||
| Full Title: Evaluation of the use of an oral direct anti-Xa anticoagulant, Apixaban in prevention of venous thromboembolic disease in patients treated with IMiDs during myeloma: a pilot study | ||
| Medical condition: Multiple myeloma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-005255-87 | Sponsor Protocol Number: 2014-13 | Start Date*: 2016-05-04 |
| Sponsor Name:Assistance Publique Hôpitaux de MARSEILLE | ||
| Full Title: Efficacy of adjuvant Imatinib in patients with intermediate-risk gastrointestinal stromal tumor with a high-risk Genomic Grade Index. Multicenter, prospective, randomized study. | ||
| Medical condition: Patients with intermediate-risk gastrointestinal stromal tumor presenting a high Genomic Grade Index | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-001332-11 | Sponsor Protocol Number: IRELANDPILOTV1 | Start Date*: 2014-07-30 |
| Sponsor Name:Royal College of Surgeons | ||
| Full Title: Aspirin for Optimising Pregnancy Outcome in Pregestational Diabetes: Pilot for The IRELAND Study (Investigating the Role of Early Low-dose Aspirin iN preexisting Diabetes) | ||
| Medical condition: Pregestational diabetes represents a high-risk for evolution of preeclampsia (PET), with rates of PET within this group at approximately 20%. The combination of diabetes and preeclampsia places the... | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: IE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-001068-31 | Sponsor Protocol Number: 2019/2894 | Start Date*: 2019-09-24 | ||||||||||||||||
| Sponsor Name:Gustave Roussy | ||||||||||||||||||
| Full Title: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) Randomized, international and multicentric phase 3 study that evaluates and compares 2 treatment strategies in 3 therapeutic p... | ||||||||||||||||||
| Medical condition: Very High Risk Neuroblastoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) SI (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) SE (Ongoing) SK (Trial now transitioned) ES (Ongoing) DE (Ongoing) AT (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2019-001834-33 | Sponsor Protocol Number: OXYLIFE | Start Date*: 2020-10-20 |
| Sponsor Name:LABORATORIO FARMACEUTICO CT SRL | ||
| Full Title: Efficacy and safety of Sodium Oxybate in reducing alcohol consumption and maintaining abstinence in alcohol-dependent subjects with high and very high drinking risk level. “OXYLIFE Study“ | ||
| Medical condition: Alcohol addiction | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: IT (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-001522-30 | Sponsor Protocol Number: RIMOFATSCI-2 | Start Date*: 2022-10-03 |
| Sponsor Name:Fundación Hospital Nacional de Parapléjicos | ||
| Full Title: Effects of a CB1 receptor reverse antagonist/agonist (Rimonabant) on wandering ability in patients with incomplete spinal cord injuries | ||
| Medical condition: Possibility of improving wandering in patients. The effects of Rimonabant on other functional measures will be assessed and it will be confirmed that it is a safe treatment in the study population. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
